CD4+ and CD8+ T-Cell responses to latent antigen EBNA-1 and lytic antigen BZLF-1 during persistent lymphocryptovirus infection of rhesus macaques

Journal of Virology

Volumn 87, Issue 15, 2013, Pages 8351-8362

  Leskowitz, R M ^a   Zhou, X Y ^a   Villinger, F ^b   Fogg, M H ^c,e   Kaur, A ^d   Lieberman, P M ^a   Wang, F ^c,d   Ertl, H C ^a  

^a WISTAR INSTITUTE   (United States)

^b EMORY UNIVERSITY   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPSTEIN BARR VIRUS ANTIGEN 1; GAMMA INTERFERON; IMMEDIATE EARLY PROTEIN BZLF1; INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; EPSTEIN BARR VIRUS INFECTION; MEMORY T LYMPHOCYTE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RHESUS MONKEY; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; DISEASE MODELS, ANIMAL; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; FEMALE; HERPESVIRIDAE INFECTIONS; LYMPHOCRYPTOVIRUS; MACACA MULATTA; TRANS-ACTIVATORS; TUMOR VIRUS INFECTIONS;

EID: 84880605302     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00852-13     Document Type: Article

References (57)

1. Landais E, Saulquin X, Houssaint E. 2005. The human T cell immune response to Epstein-Barr virus. Int. J. Dev. Biol. 49:285-292
2. Kerr BM, Lear AL, Rowe M, Croom-Carter D, Young LS, Rookes SM,Gallimore PH, Rickinson AB. 1992. Three transcriptionally distinct forms of Epstein-Barr virus latency in somatic cell hybrids: cell phenotype dependence of virus promoter usage. Virology 187:189-201.
3. Schooley RT, Arbit DI, Henle W, Hirsch MS. 1984. T-lymphocyte subset interactions in the cell-mediated immune response to Epstein-Barr virus. Cell Immunol. 86:402-412.
4. Parkin DM. 2006. The global health burden of infection-associated cancers in the year 2002. Int. J. Cancer 118:3030-3044.
5. Henle W, Henle G. 1974. The Epstein-Barr Virus (EBV) in Burkitt's lymphoma and nasopharyngeal carcinoma. Ann. Clin. Lab Sci. 4:109-114.
6. Mueller N. 1987. Epidemiologic studies assessing the role of the EpsteinBarr virus in Hodgkin's disease. Yale J. Biol. Med. 60:321-332.
7. Quadrelli C, Barozzi P, Riva G, Vallerini D, Zanetti E, Potenza L, Forghieri F, Luppi M. 2011.β-HHVs and HHV-8 in lymphoproliferative disorders. Mediterr. J. Hematol. Infect. Dis. 3:e2011043. doi:10.4084/MJHID.2011.043.
8. Posnett DN. 2008. Herpesviruses and autoimmunity. Curr. Opin. Investig. Drugs 9:505-514
9. Garzelli C, Pacciardi A, Carmignani M, Conaldi G, Basolo F, Falcone G. 1989. A human monoclonal autoantibody isolated from a patient with infectious mononucleosis reactive with both self antigens and Epstein-Barr virus nuclear antigen (EBNA). Immunol. Lett. 22:211-216.
10. Dreyfus DH. 2011. Autoimmune disease: a role for new anti-viral therapies? Autoimmun. Rev. 11:88-97.
11. Epstein MA, Randle BJ, Finerty S, Kirkwood JK. 1986. Not all potently neutralizing, vaccine-induced antibodies to Epstein-Barr virus ensure protection of susceptible experimental animals. Clin. Exp. Immunol. 63: 485-490.
12. Ckey TD, Zhan X, Surman S, Sample CE, Hurwitz JL. 2008. Epstein-Barr virus vaccine development: a lytic and latent protein cocktail. Front.Biosci. 13:5916-5927.
13. Sivachandran N, Wang X, Frappier L. 2012. Functions of the EpsteinBarr virus EBNA1 protein in viral reactivation and lytic infection. J. Virol. 86:6146-6158
14. Munz C. 2004. Epstein-Barr virus nuclear antigen 1: from immunologically invisible to a promising T cell target. J. Exp. Med. 199:1301-1304.
15. Levitskaya J, Sharipo A, Leonchiks A, Ciechanover A, Masucci MG. 1997. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proc. Natl. Acad. Sci. U. S. A. 94:12616-12621.
16. Lee SP, Brooks JM, Al-Jarrah H, Thomas WA, Haigh TA, Taylor GS,Humme S, Schepers A,Hammerschmidt W, Yates JL, Rickinson AB,Blake NW. 2004. CD8 T cell recognition of endogenously expressed Epstein-Barr virus nuclear antigen 1. J. Exp. Med. 199:1409-1420.
17. + T lymphocytes consistently respond to the latent Epstein-Barr virus nuclearantigen EBNA1. J. Exp. Med. 191:1649-1660.
18. +-Tcell clones reactive to EBNA1 inhibit Epstein-Barr virus-induced B-cell proliferation. J. Virol. 77:12088-12104.
19. + T cells in patients with Epstein-Barr virus-associated nasopharyngeal carcinoma. Proc. Natl. Acad. Sci. U. S. A. 106:3318-3323.
20. + T cells in the control of mouse Burkitt lymphoma in vivo. J. Clin. Invest. 114:542-550.
21. + T-cell responses to the viral nuclear antigen 1. Int. J.Cancer 123:2824-2831.
22. Moormann AM, Heller KN, Chelimo K, Embury P, Ploutz-Snyder R,Otieno JA, Oduor M, Munz C, Rochford R. 2009. Children with endemic Burkitt lymphoma are deficient in EBNA1-specific IFN-gamma T cell responses. Int. J. Cancer 124:1721-1726.
23. + T cells in HIV-infected patients progressing to AIDS-related non-Hodgkin lymphoma. Blood 106:3166-3174.
24. Moghaddam A, Rosenzweig M, Lee-Parritz D, Annis B, Johnson RP,Wang F. 1997. An animal model for acute and persistent Epstein-Barr virus infection. Science 276:2030-2033.
25. Rivailler P, Carville A, Kaur A, Rao P, Quink C, Kutok JL, Westmoreland S, Klumpp S, Simon M, Aster JC, Wang F. 2004. Experimental rhesus lymphocryptovirus infection in immunosuppressed macaques: an animal model for Epstein-Barr virus pathogenesis in the immunosuppressed host. Blood 104:1482-1489.
26. Blake NW, Moghaddam A, Rao P, Kaur A, Glickman R, Cho YG, Marchini A, Haigh T, Johnson RP, Rickinson AB, Wang F. 1999. Inhibition of antigen presentation by the glycine/alanine repeat domain is not conserved in simian homologues of Epstein-Barr virus nuclear antigen 1. J. Virol. 73:7381-7389.
27. + T cells specific for late lytic infection antigens in lymphocryptovirus-infected macaques and Epstein-Barr virus-infected humans. J. Virol. 85:12821-12824.
28. Ruf IK, Moghaddam A, Wang F, Sample J. 1999. Mechanisms that regulate Epstein-Barr virus EBNA-1 gene transcription during restricted latency are conserved among lymphocryptoviruses of Old World primates. J. Virol. 73:1980-1989.
29. Carville A, Mansfield KG. 2008. Comparative pathobiology of macaque lymphocryptoviruses. Comp. Med. 58:57-67.
30. Wang F, Rivailler P, Rao P, Cho Y. 2001. Simian homologues of Epstein-Barr virus. Philos. Trans. R. Soc. Lond. B Biol. Sci. 356:489-497.
31. Rivailler P, Cho YG, Wang F. 2002. Complete genomic sequence of an T-Cell Responses in Rhesus LCV Infection August 2013 Epstein-Barr virus-related herpesvirus naturally infecting a new world primate: a defining point in the evolution of oncogenic lymphocryptoviruses.J. Virol. 76:12055-12068.
32. + T-cell response to an Epstein-Barr virus-related gammaherpesvirus infecting rhesus macaques provides evidence for immune evasion by the EBNA-1 homologue. J. Virol. 79:12681-12691.
33. Rao P, Jiang H, Wang F. 2000. Cloning of the rhesus lymphocryptovirus viral capsid antigen and Epstein-Barr virus-encoded small RNA homologues and use in diagnosis of acute and persistent infections. J. Clin. Microbiol. 38:3219-3225.
34. McCoy K, Tatsis N, Korioth-Schmitz B, Lasaro MO, Hensley SE, Lin SW, Li Y, Giles-Davis W, Cun A, Zhou D, Xiang Z, Letvin NL, Ertl HC. 2007. Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors. J. Virol. 81:6594-6604.
35. Lasaro MO, Haut LH, Zhou X, Xiang Z, Zhou D, Li Y, Giles-Davis W, Li H, Engram JC, Dimenna LJ, Bian A, Sazanovich M, Parzych EM, Kurupati R, Small JC, Wu TL, Leskowitz RM, Klatt NR, Brenchley JM, Garber DA, Lewis M, Ratcliffe SJ, Betts MR, Silvestri G, Ertl HC. 2011. Vaccine-induced T cells provide partial protection against high-dose rectal SIVmac239 challenge of rhesus macaques. Mol. Ther. 19:417-426.
36. Elliott SL, Pye SJ, Schmidt C, Cross SM, Silins SL, Misko IS. 1997. Dominant cytotoxic T lymphocyte response to the immediate-early transactivator protein, BZLF1, in persistent type A or B Epstein-Barr virus infection. J. Infect. Dis. 176:1068-1072.
37. Fogg MH, Garry D, Awad A, Wang F, Kaur A. 2006. The BZLF1 homolog of an Epstein-Barr-related gamma-herpesvirus is a frequent target of the CTL response in persistently infected rhesus macaques. J. Immunol. 176:3391-3401.
38. Kannanganat S, Ibegbu C, Chennareddi L, Robinson HL, Amara RR. 2007. Multiple-cytokine-producing antiviral CD4 T cells are functionally superior to single-cytokine-producing cells. J. Virol. 81:8468-8476.
39. + T cell responses. J. Exp. Med. 204:1405-1416.
40. Stuber G, Dillner J, Modrow S, Wolf H, Szekely L, Klein G, Klein E. 1995. HLA-A0201 and HLA-B7 binding peptides in the EBV-encoded EBNA-1, EBNA-2 and BZLF-1 proteins detected in the MHC class I stabilization assay. Low proportion of binding motifs for several HLA class I alleles in EBNA-1. Int. Immunol. 7:653-663.
41. +, interferon-gamma-secreting, T lymphocytes. Eur. J. Immunol. 29:3995-4001.
42. + T cells in healthy carriers of Epstein-Barr virus are primarily Th1 in function. J. Clin. Invest. 107:121-130.
43. Houssaint E, Saulquin X, Scotet E, Bonneville M. 2001. Immunodominant CD8 T cell response to Epstein-Barr virus. Biomed. Pharmacother.55:373-380
44. + T cells specific for EBV in healthy virus carriers. J. Immunol. 162:1827-1835.
45. Woodberry T, Suscovich TJ, Henry LM, Davis JK, Frahm N, Walker BD, Scadden DT, Wang F, Brander C. 2005. Differential targeting and shifts in the immunodominance of Epstein-Barr virus-specific CD8 and CD4 T cell responses during acute and persistent infection. J. Infect. Dis. 192:1513-1524.
46. + T cell responses to EBV contrast with CD8 responses in breadth of lytic cycle antigen choice and in lytic cycle recognition. J. Immunol. 187:92-101.
47. + T-cell subsets mediate immune recognition of Epstein Barr virus nuclear antigen 1 in healthy virus carriers. Blood 109:1138-1146.
48. Guerreiro M, Na IK, Letsch A, Haase D, Bauer S, Meisel C, Roemhild A, Reinke P, Volk HD, Scheibenbogen C. 2010. Human peripheral blood and bone marrow Epstein-Barr virus-specific T-cell repertoire in latent infection reveals distinct memory T-cell subsets. Eur. J. Immunol. 40:1566-1576.
49. + polyfunctional T-cell responses which show immunodominance hierarchies of EBV proteins. Immunology 134:161-171.
50. Hislop AD, Taylor GS, Sauce D, Rickinson AB. 2007. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu. Rev. Immunol. 25:587-617.
51. Sugano N, Ikeda K, Oshikawa M, Idesawa M, Tanaka H, Sato S, Ito K. 2004. Relationship between Porphyromonas gingivalis, Epstein-Barr virus infection and reactivation in periodontitis. J. Oral Sci. 46:203-206.
52. + T cell response to Epstein-Barr virus lytic antigens in the active phase of multiple sclerosis. PLoS Pathog. 9:e1003220. doi:10.1371/journal.ppat.1003220.
53. Glaser R, Pearl DK, Kiecolt-Glaser JK, Malarkey WB. 1994. Plasma cortisol levels and reactivation of latent Epstein-Barr virus in response to examination stress. Psychoneuroendocrinology 19:765-772.
54. Stowe RP, Pierson DL, Feeback DL, Barrett AD. 2000. Stress-induced reactivation of Epstein-Barr virus in astronauts. Neuroimmunomodulation 8:51-58.
55. Minhas V, Brayfield BP, Crabtree KL, Kankasa C, Mitchell CD, Wood C. 2010. Primary gamma-herpesviral infection in Zambian children. BMC Infect. Dis. 10:115. doi:10.1186/1471-2334-10-115.
56. + T cell responses during infectious mononucleosis. Clin. Exp. Immunol. 153:231-239.
57. + T-cell differentiation. J. Virol. 87:1779-1788.